Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP170806.RAEI9tDXUhx_Rx5FciZ6O_Yh8QV-kESjw68NVUfLXvVxs130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP170806.RAEI9tDXUhx_Rx5FciZ6O_Yh8QV-kESjw68NVUfLXvVxs130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP170806.RAEI9tDXUhx_Rx5FciZ6O_Yh8QV-kESjw68NVUfLXvVxs130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP170806.RAEI9tDXUhx_Rx5FciZ6O_Yh8QV-kESjw68NVUfLXvVxs130_provenance.
- NP170806.RAEI9tDXUhx_Rx5FciZ6O_Yh8QV-kESjw68NVUfLXvVxs130_assertion description "[The aim of this study was to evaluate the response and resistance of cases to chronic myeloid leukemia (CML) therapy with tyrosine kinase (TK) inhibitors (imatinib mesylate) and to search for mutations in the breakpoint cluster region (BCR)-Abelson murine leukemia (ABL) kinase domain prior to and during therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP170806.RAEI9tDXUhx_Rx5FciZ6O_Yh8QV-kESjw68NVUfLXvVxs130_provenance.
- NP170806.RAEI9tDXUhx_Rx5FciZ6O_Yh8QV-kESjw68NVUfLXvVxs130_assertion evidence source_evidence_literature NP170806.RAEI9tDXUhx_Rx5FciZ6O_Yh8QV-kESjw68NVUfLXvVxs130_provenance.
- NP170806.RAEI9tDXUhx_Rx5FciZ6O_Yh8QV-kESjw68NVUfLXvVxs130_assertion SIO_000772 19943786 NP170806.RAEI9tDXUhx_Rx5FciZ6O_Yh8QV-kESjw68NVUfLXvVxs130_provenance.
- NP170806.RAEI9tDXUhx_Rx5FciZ6O_Yh8QV-kESjw68NVUfLXvVxs130_assertion wasDerivedFrom befree-20140225 NP170806.RAEI9tDXUhx_Rx5FciZ6O_Yh8QV-kESjw68NVUfLXvVxs130_provenance.
- NP170806.RAEI9tDXUhx_Rx5FciZ6O_Yh8QV-kESjw68NVUfLXvVxs130_assertion wasGeneratedBy ECO_0000203 NP170806.RAEI9tDXUhx_Rx5FciZ6O_Yh8QV-kESjw68NVUfLXvVxs130_provenance.
- befree-20140225 importedOn "2014-02-25" NP170806.RAEI9tDXUhx_Rx5FciZ6O_Yh8QV-kESjw68NVUfLXvVxs130_provenance.